Stocktoria
NEUROONE MEDICAL TECHNOLOGIES Corp NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $9.1M at a -39.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 0.05 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.735 |
| Retained earnings / assets | -7.288 |
| EBIT / assets | -0.392 |
| Equity / liabilities | 1.905 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
| NXGL | NEXGEL, INC. | 5/9 | -6.91 | — | — |
About NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.
FAQ
Is NMTC financially healthy?
NEUROONE MEDICAL TECHNOLOGIES Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NMTC pay a dividend?
No, NEUROONE MEDICAL TECHNOLOGIES Corp does not currently pay a dividend.
How profitable is NMTC?
In FY2025, NEUROONE MEDICAL TECHNOLOGIES Corp had a net margin of -39.6% and a return on equity of -51.0%.
What is the analyst price target for NMTC?
The average Wall-Street price target for NEUROONE MEDICAL TECHNOLOGIES Corp is $9.93, about 553.5% above the recent price, from 3 analysts (consensus: strong buy).
Is NMTC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEUROONE MEDICAL TECHNOLOGIES Corp: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.